Inventor
BROGDON JENNIFER
US39 patents
⚠️ This page may combine multiple inventors who share the name “BROGDON JENNIFER”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
NOVARTIS AG
32 patentsUS10174095B2Jan 8, 2019
Nucleic acid encoding a humanized anti-BCMA chimeric antigen receptor
NOVARTIS AG41 citations96
US10221245B2Mar 5, 2019
Treatment of cancer using humanized anti-CD19 chimeric antigen receptor
NOVARTIS AG36 citations94
US11084880B2Aug 10, 2021
Anti-BCMA chimeric antigen receptor
NOVARTIS AG15 citations93
US10525083B2Jan 7, 2020
Nucleic acid molecules encoding chimeric antigen receptors comprising a CD20 binding domain
NOVARTIS AG15 citations93
US10253086B2Apr 9, 2019
CD20 therapies, CD22 therapies, and combination therapies with a CD19 chimeric antigen receptor (CAR)-expressing cell
NOVARTIS AG37 citations93
US10287354B2May 14, 2019
Regulatable chimeric antigen receptor
NOVARTIS AG29 citations92
US10927184B2Feb 23, 2021
Treatment of cancer using humanized anti-CD19 chimeric antigen receptor
NOVARTIS AG10 citations86
US11149076B2Oct 19, 2021
CD20 therapies, CD22 therapies, and combination therapies with a CD19 chimeric antigen receptor (CAR)-expressing cell
NOVARTIS AG9 citations84
US10308717B2Jun 4, 2019
Treatment of cancer using humanized anti-EGFRvIII chimeric antigen receptor
NOVARTIS AG4 citations83
US11026976B2Jun 8, 2021
Nucleic acid molecules encoding chimeric antigen receptors comprising a CD20 binding domain
NOVARTIS AG6 citations82
US10774388B2Sep 15, 2020
Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof
NOVARTIS AG7 citations80
US12344657B2Jul 1, 2025
CD20 therapies, CD22 therapies, and combination therapies with a CD19 chimeric antigen receptor (CAR)-expressing cell
NOVARTIS AG1 citations73
US11028177B2Jun 8, 2021
Effective targeting of primary human leukemia using anti-CD123 chimeric antigen receptor engineered T cells
NOVARTIS AG4 citations73
US11865167B2Jan 9, 2024
Treatment of cancer using humanized anti-EGFRvIII chimeric antigen receptor
NOVARTIS AG2 citations72
US11413340B2Aug 16, 2022
Mesothelin chimeric antigen receptor (CAR) and antibody against PD-L1 inhibitor for combined use in anticancer therapy
NOVARTIS AG2 citations72
US11872249B2Jan 16, 2024
Method of treating cancer by administering immune effector cells expressing a chimeric antigen receptor comprising a CD20 binding domain
NOVARTIS AG2 citations71
US11542488B2Jan 3, 2023
Sortase synthesized chimeric antigen receptors
NOVARTIS AG2 citations71
US10568947B2Feb 25, 2020
Treatment of cancer using a CLL-1 chimeric antigen receptor
NOVARTIS AG6 citations71
US10662247B2May 26, 2020
Compositions and methods of use for augmented immune response and cancer therapy
NOVARTIS AG2 citations70
US9982046B2May 29, 2018
Methods of treating cardiovascular disorders with lectin-like oxidized LDL receptor 1 antibodies
NOVARTIS AG2 citations70
US9988455B2Jun 5, 2018
Methods of treating cardiovascular disorders with lectin-like oxidized LDL receptor 1 antibodies
NOVARTIS AG3 citations69
US12559562B2Feb 24, 2026
Treatment of cancer using humanized anti-EGFRvIII chimeric antigen receptor
NOVARTIS AG0 citations62
US12186278B2Jan 7, 2025
Mesothelin chimeric antigen receptor (CAR) and antibody against PD-L1 inhibitor for combined use in anticancer therapy
NOVARTIS AG0 citations62
US11591404B2Feb 28, 2023
Treatment of cancer using a CD123 chimeric antigen receptor
NOVARTIS AG0 citations62
US10703819B2Jul 7, 2020
Treatment of cancer using a CD123 chimeric antigen receptor
NOVARTIS AG1 citations62
US12594321B2Apr 7, 2026
Bispecific chimeric antigen receptor that binds CD19 and CD20, encoding nucleic acid molecules thereof and methods of use thereof to treat cancer
NOVARTIS AG0 citations61
USRE49847EFeb 27, 2024
Nucleic acid molecules encoding chimeric antigen receptors comprising a CD20 binding domain
NOVARTIS AG0 citations61
US11578130B2Feb 14, 2023
Regulatable chimeric antigen receptor
NOVARTIS AG1 citations61
US11459390B2Oct 4, 2022
Phosphoglycerate kinase 1 (PGK) promoters and methods of use for expressing chimeric antigen receptor
NOVARTIS AG0 citations61
US12383601B2Aug 12, 2025
Chimeric antigen receptors and uses thereof
NOVARTIS AG1 citations57
US11851659B2Dec 26, 2023
Compositions and methods for immunooncology
NOVARTIS AG0 citations57
US10870698B2Dec 22, 2020
Nucleic acids encoding lectin-like oxidized LDL receptor 1 antibodies
NOVARTIS AG0 citations49
BROGDON JENNIFER
3 patentsUS9815901B2Nov 14, 2017
Treatment of cancer using a CD123 chimeric antigen receptor
BROGDON JENNIFER94 citations97
US9573988B2Feb 21, 2017
Effective targeting of primary human leukemia using anti-CD123 chimeric antigen receptor engineered T cells
BROGDON JENNIFER87 citations97
US9394368B2Jul 19, 2016
Treatment of cancer using humanized anti-EGFRvIII chimeric antigen receptor
BROGDON JENNIFER112 citations97